Murine models of sporadic and inflammation-related colon carcinogenesis with particular focus on the AOM/DSS chemically induced colorectal cancer model

Animal Models in Cancer Research and Human Disease: Applications, Outcomes and Controversies

Volumn , Issue , 2013, Pages 1-45

  De Robertis, M ^a   Fazio, V M ^a,b   Signori, E ^a  

^a CNR   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

AOM DSS Murine Model; Chemical Carcinogenesis; Colorectal Cancer Animal Models; Colorectal Carcinogenesis

Indexed keywords

EID: 84892030184     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (125)

1. Haggar, FA; Boushey, RP. Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors. Clin. Colon Rectal Surg. 2009,22,191-197.
2. van Hogezand, RA; Eichhorn, RF; Choudry, A; Veenendaal, RA; Lamers, BHW. Malignancies in inflammatory bowel disease: fact or fiction? Scand. J. Gastroenterol. Suppl. 2002,235,48-53.
3. Gala, M; Chung, DC. Hereditary colon cancer syndromes. Semin. Oncol. 2011;38,490-9.
4. Al-Sohaily, S; Biankin, A; Leong, R; Kohonen-Corish, M; Warusavitarne, J. Molecular pathways in colorectal cancer. J. Gastroenterol. Hepatol. 2012,27,1423-1431.
5. Friedman, E; Urmacher, C; Winawer, S. A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 1984,44,1568-78.
6. Fodde, R; Smits, R. Disease model: familial adenomatous polyposis. Trends Mol. Med. 2001,7,369-73.
7. Takaku, K; Sonoshita, M; Sasaki, N; Uozumi, N; Doi, Y; Shimizu, T; Taketo, MM. Suppression of intestinal polyposis in Apc (delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J. Biol. Chem. 2000,275,34013-6.
8. Oshima, M; Dinchuk, JE; Kargman, SL; Oshima, H; Hancock, B; Kwong, E; Trzaskos, JM; Evans, JF; Taketo, MM. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996,87,803-9.
9. Seno, H; Oshima, M; Ishikawa, TO; Oshima, H; Takaku, K; Chiba, T; Narumiya, S; Taketo, MM. Cyclooxygenase 2-and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 2002,62,506-11.
10. Heyer, J; Yang, K; Lipkin, M; Edelmann, W; Kucherlapati R. Mouse models for colorectal cancer. Oncogene 1999,18,5325-33.
11. Garofalo, A; Chirivi, RG; Scanziani, E; Mayo, JG; Vecchi, A; Giavazzi, R. Comparative study on the metastatic behavior of human tumors in nude, beige/nude/xid and severe combined immunodeficient mice. Invasion Metastasis 1993,13,82-91.
12. Zigmond, E; Halpern, Z; Elinav, E; Brazowski, E; Jung, S; Varol, C. Utilization of Murine Colonoscopy for Orthotopic Implantation of Colorectal Cancer. PLoS ONE 2011,6,e28858.
13. Ito, N; Hasegawa, R; Sano, M; Tamano, S; Esumi, H; Takayama, S; Sugimura, T. A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP). Carcinogenesis 1991, 12, 1503-150.
14. Kato, T; Ohgaki, H; Hasegawa, H; Sato, S; Takayama, S; Sugimura T. Carcinogenicity in rats of a mutagenic compound, 2-amino-3,8-dimethylimidazo [4,5-f]quinoxaline. Carcinogenesis 1988, 9,71-73.
15. Hasegawa, R; Sano, M; Tamano, S; Imaida, K; Shirai, T; Nagao, M; Sugimura, T; Ito, N. Dose-dependence of 2-amino-1-methyl-6-phenylimidazo [4,5-b]-pyridine (PhIP) carcinogenicity in rats. Carcinogenesis 1993,14,2553-7.
16. Reddy, BS; Rivenson, A. Inhibitory effect of Bifidobacterium longum on colon, mammary, and liver carcinogenesis induced by 2-amino-3-methylimidazo [4,5-f] quinoline, a food mutagen. Cancer Res. 1993,53,3914-8.
17. Doi, K; Wanibuchi, H; Salim, EI; Morimura, K; Kinoshita, A; Kudoh, S; Hirata, K; Yoshikawa, J; Fukushima, S. Lack of large intestinal carcinogenicity of 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine at low doses in rats initiated with azoxymethane. Int. J. Cancer 2005,115,870-8.
18. Kobaek-Larsen, M; Thorup, I; Diederichsen, A; Fenger, C; Hoitinga, MR. Review of colorectal cancer and its metastases in rodent models: comparative aspects with those in humans. Comp. Med. 2000,50,16-26.
19. Walpole, A; Williams, MH; Roberts, DC. The carcinogenic action of 4-aminodiphenyl and 3:2'-dimethyl-4-amino-diphenyl. Br. J. Ind. Med. 1952,9,255-63.
20. Reddy, BS; Ohmori, T. Effect of intestinal microflora and dietary fat on 3,2'-dimethyl-4-aminobiphenyl-induced colon carcinogenesis in F344 rats. Cancer Res. 1981,41,1363-7.
21. Narisawa, T; Magadia, NE; Weisburger, JH; Wynder, EL. Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N'-nitro-N-nitrosoguanidine in rats. J. Natl. Cancer Inst. 1974,53,1093-7.
22. Heijstek MW, Kranenburg O, Borel Rinkes IH. Mouse models of colorectal cancer and liver metastases. Dig. Surg. 2005,22,16-25.
23. Laqueur, GL, Mickelsen, O; Whiting, MG; Kurland, LT. Carcinogenic Properties of Nuts from Cycas Circinalis L. Indigenous to Guam. J. Natl. Cancer Inst. 1963,31,919-51.
24. Martin, MS; Martin, F, Michiels, R; Bastien, H; Justrabo, E; Bordes, M; Viry, B. An experimental model for cancer of the colon and rectum. Intestinal carcinoma induced in the rat 1,2-dimethylhydrazine. Digestion 1973,8,22-34.
25. Ward, JM. Morphogenesis of chemically induced neoplasms of the colon and small intestine in rats. Lab. Invest 1974,30,505-13.
26. Sohn, OS; Fiala, ES; Requeijo, SP; Weisburger, JH; Gonzalez, FJ. Differential effects of CYP2E1 status on the metabolic activation of the colon carcinogens azoxymethane and methylazoxymethanol Cancer Res. 2001,61,8435-40.
27. Papanikolaou, A; Wang, QS; Delker, DA; Rosenberg, DW. Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility. Cancer Lett. 1998,130,29-34.
28. Papanikolaou, A; Wang, QS; Mulherkar, R; Bolt, A; Rosenberg, DW. Expression analysis of the group IIA secretory phospholipase A(2) in mice with differential susceptibility to azoxymethane-induced colon tumorigenesis. Carcinogenesis 2000,21,133-8.
29. Tanaka, T; Kohno, H; Suzuki, R; Yamada, Y; Sugie, S; Mori, H. A novel inflammation related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 2003,94,965-73.
30. De Robertis, M; Massi, E; Poeta, ML; Carotti, S; Morini, S; Cecchetelli, L; Signori, E; Fazio, VM. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J. Carcinog. 2011,24,10-9.
31. Neufert, C; Becker, C; Neurath, MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat. Protoc. 2007,2,1998-2004.
32. Clapp, NK; Henke, MA; London, JF; Shock TL. Enhancement of 1,2-dimethylhydrazine-induced large bowel tumorigenesis in Balb/c mice by corn, soybean, and wheat brans. Nutr. Cancer 1984,6,77-85.
33. Hata, K; Yamada, Y; Kuno, T; Hirose, Y; Hara, A; Qiang, SH; Mori, H. Tumor formation is correlated with expression of beta-catenin-accumulated crypts in azoxymethane-induced colon carcinogenesis in mice. Cancer Sci. 2004,95,316-20.
34. Papanikolaou, A; Wang, QS; Papanikolaou, D; Whiteley, HE; Rosenberg, DW. Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis 2000,21,1567-72.
35. Bissahoyo, A; Pearsall, RS; Hanlon, K; Amann, V; Hicks, D; Godfrey, VL; Threadqill, DW. Azoxymethane is a genetic background-dependent colorectal tumor initiator and promoter in mice: effects of dose, route, and diet. Toxicol. Sci. 2005,88,340-5.
36. Okayasu, I; Ohkusa, T; Kajiura, K; Kanno, J; Sakamoto S. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 1996,39,87-92.
37. Becker, C; Fantini, MC; Schramm, C; Lehr, HA; Wirtz, S; Nikolaev, A; Burg, J; Strand, S; Kiesslich, R; Huber, S; Ito, H; Nishimoto, N; Yoshizaki, K; Kishimoto, T; Galle, PR; Blessing, M; Rose-John S, Neurath MF. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004,21,491-501.
38. Becker, C; Fantini, MC; Wirtz, S; Nikolaev, A; Kiesslich, R; Lehr, HA; Galle, PR; Neurath, MF. In vivoimagingofcolitisandcolon cancerdevelopmentinmice using high resolution chromoendoscopy. Gut 2005,54,950-4.
39. Rosenberg, DW; Giardina, C; Tanaka, T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 2009,30,183-96.
40. Salim, EI; Wanibuchi, H; Morimura, K; Murai, T; Makino, S; Nomura, T; Fukushima, S. Induction of tumors in the colon and liver of the immunodeficient (SCID) mouse by 2-amino-3-methylimidazo [4,5-f]quinoline (IQ)-modulation by long-chain fatty acids. Carcinogenesis 2002,23,1519-29.
41. Mølck, AM; Meyer, O; Kristiansen, E; Thorup, I. IQ (2-amino-3-methylimidazo [4,5-f]quinoline)-induced aberrant crypt foci and colorectal tumour development in rats fed two different carbohydrate diets. Eur. J. Cancer Prev. 2001,10,501-6.
42. Ito, N; Hasegawa, R; Imaida, K; Tamano, S; Hagiwara, A; Hirose, M; Shirai, T. Carcinogenicity of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) in the rat. Mutat Res. 1997,376,107-14.
43. Wang, R; Dashwood, WM; Löhr, CV; Fischer, KA; Pereira, CB; Louderback, M; Nakagama, H; Bailey, GS; Williams, DE; Dashwood, RH. Protective versus promotional effects of white tea and caffeine on PhIP-induced tumorigenesis and β-catenin expression in the rat. Carcinogenesis 2008,29,834-839.
44. Nakagama, H; Ochiai, M; Ubagai, T; Tajima, R; Fujiwara, K; Sugimura, T; Nagao, M. A rat colon cancer model induced by 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine, PhIP. Mutat Res. 2002,506-507,137-44.
45. Yang, J; Shikata, N; Mizuoka, H; Tsubura, A. Colon carcinogenesis in shrews by intrarectal infusion of N-methyl-N-nitrosourea. Cance Lett. 1996,110,105-112.
46. Zusman, I; Zimber, A; Nyska, A. Role of morphological methods in the analysis of chemically induced colon cancer in rats. Acta Anat. Basel 1991,142,351-356.
47. Nambiar, PR; Girnun, G; Lillo, NA; Guda, K; Whiteley, HE; Rosenberg, DW. Preliminary analysis of azoxymethane induced colon tumors in inbred mice commonly used as transgenic/knockout progenitors. Int. J. Oncol. 2003,22,145-50.
48. Kim, YJ; Hong, KS; Chung, JW; Kim, JH; Hahm, KB. Prevention of colitis-associated carcinogenesis with infliximab. Cancer Prevention Research 2010,3,1314-1333.
49. Nishikawa, A; Imazawa, T; Kuroiwa, Y; Kitamura, Y; Kanki, K; Ishii; Y; Umemura, T; Hirose, M. Induction of colon tumors in C57BL/6J mice fed MeIQx, IQ, or PhIP followed by dextran sulfate sodium. Toxicol. Sci. Toxicol. Sci. 2005,84,243-8.
50. Meira, LB; Bugni, JM; Green, SL; Lee, CW; Pang, B; Borenshtein, D; Rickman, BH; Rogers, AB; Moroski-Erkul, CA; McFaline, JL; Schauer, DB; Dedon, PC; Fox, JG; Samson, LD. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J. Clin. Invest. 2008,118,2516-25.
51. Suzuki, R; Kohno, H; Sugie, S; Nakagama, H; Tanaka, T. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis 2006,27,162-9.
52. Bird, RP; Good, CK. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol. Lett. 2000, 112,395-402.
53. Yamada, Y; Yoshimi, N; Hirose, Y; Matsunaga, K; Katayama, M; Sakata, K; Shimizu, M; Kuno, T; Mori, H. Sequential analysis of morphological and biological properties of beta-catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res. 2001,61,1874-8.
54. Caderni, G; Femia, AP; Giannini, A; Favuzza, A; Luceri, C; Salvadori, M; Dolara, P. Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res. 2003,63,2388-92.
55. Paulsen, JE; Løberg, EM; Olstørn, HB; Knutsen, H; Steffensen, IL; Alexander, J. Flat dysplastic aberrant crypt foci are related to tumorigenesis in the colon of azoxymethane-treated rat. Cancer Res. 2005,65,121-9.
56. Yasui, Y; Tanaka T. Protein expression analysis of inflammation-related colon carcinogenesis. J. Carcinog. 2009,8,10.
57. Gerling, M; Glauben, R; Habermann, JK; Kuhl, AA; Loddenkemper, C; Lehr, AH; Zeitz, M; Siegmund, B. Characterization of Chromosomal Instability in Murine Colitis-Associated Colorectal Cancer. PLoS ONE 2011,6,e22114.
58. Cooper, HS; Murthy, S; Kido, K; Yoshitake, H; Flanigan, A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitisassociated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000,21,757-68.
59. Kohno, H; Suzuki, R; Sugie, S; Tanaka, T. Beta-Catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci. 2005,96,69-76.
60. Svec, J; Ergang, P; Mandys, V; Kment, M; Pácha, J. Expression profiles of proliferative and antiapoptotic genes in sporadic and colitis-related mouse colon cancer models. Int. J. Exp. Path 2010,91,44-53.
61. Jacoby, RF; Llor, X; Teng, BB; Davidson, NO; Brasitus, TA. Mutations in the K-ras oncogene induced by 1,2-dimethylhydrazine in preneoplastic and neoplastic rat colonic mucosa. J. Clin. Invest. 1991,87,624-30.
62. Yekkala, K; Baudino, TA. Inhibition of intestinal polyposis with reduced angiogenesis in ApcMin/+ mice due to decreases in c-Myc expression. Mol. Cancer Res. 2007,5,1296-303.
63. Suzuki, R; Miyamoto, S; Yasui, Y; Sugie, S; Tanaka, T. Global gene expression analysis of the mouse colonic mucosa treated with azoxymethane and dextran sodium sulfate. BMC Cancer 2007,7,84.
64. Choi, J; Southworth, LK; Sarin, KY; Venteicher, AS; Ma, W; Chang, W; Cheung, P; Jun, S; Artandi, MK; Shah, N; Kim, SK; Artandi, SE. TERT promotes epithelial proliferation through transcriptional control of a Myc-and Wnt-related developmental program. PLoS Genet 2008,4,e10.
65. Becker, C; Fantini, MC; Neurath, MF. TGF-beta as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev. 2006,17,97-106.
66. DuBois, RN; Radhika, A; Reddy, BS; Entingh, AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996,110,1259-1262.
67. Guda, K; Giardina, C; Nambiar, P; Cui, H; Rosenberg, DW. Aberrant transforming growth factor-β signaling in azoxymethane-induced mouse colon tumors. Molecular Carcinogenesis 2001,31, 204-213.
68. Relan, NK; Saeed, A; Ponduri, K; Fligiel, SEG; Dutta, S; Majumdar, APN. Identification and evaluation of the role of endogenous tyrosine kinases in azoxymethane induction of proliferative processes in the colonic mucosa of rats. Biochimica et Biophysica Acta 1995, 1244,2-3,368-376.
69. Sinicrope, FA; Gill, S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev. 2004,23,63-75.
70. Kim, HS; Kundu, JK; Le, JS; Oh, TY; Na, HK; Surh, YJ. Chemopreventive effects of the standardized extract (DA-9601) of Artemisia asiatica on azoxymethaneinitiated and dextran sulfate sodium-promoted mouse colon carcinogenesis. Nutr. Cancer 2008,60,90-7.
71. Seril, DN; Liao, J; Yang, GY. Colorectal carcinoma development in inducible nitric oxide synthase-deficient mice with dextran sulfate sodium-induced ulcerative colitis. Mol. Carcinog. 2007,46,341-53.
72. Kohno, H; Suzuki, R; Curini, M; Epifano, F; Maltese, F; Gonzales, SP; Tanaka, T. Dietary administration with prenyloxycoumarins, auraptene and collinin, inhibits colitis-related colon carcinogenesis in mice. Int. J. Cancer 2006,118,2936-42.
73. Takahashi, M; Mutoh, M; Kawamori, T; Sugimura, T; Wakabayashi, K. Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis 2000,21,1319-27.
74. Nambiar, PR; Giardina, C; Guda, K; Aizu, W; Raja, R; Rosenberg, DW. Role of the alternating reading frame (P19)-p53 pathway in an in vivo murine colon tumor model. Cancer Res. 2002,62,3667-74.
75. Gaudet, F; Hodgson, JG; Eden, A; Jackson-Grusby, L; Dausman, J; Gra, JW; Leonhardt, H; Jaenisch, R. Induction of tumors in mice by genomic hypomethylation. Science 2003,300,489-92.
76. Borinstein, SC; Conerly, M; Dzieciatkowski, S; Biswas, S; Washington, MK; Trobridge, P; Henikoff, S; Grady, WM. Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model. Mol. Carcinog. 2010,49,94-103.
77. Nagamine, CM; Rogers, AB; Fox, JG; Schauer, DB. Helicobacter hepaticus promotes azoxymethane-initiated colon tumorigenesis in BALB/c-IL10-deficient mice. International Journal of Cancer 2008,122,832-838.
78. Okayasu, I; Yamada, M; Mikami, T; Yoshida, T; Kanno, J; Ohkusa, T. Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J. Gastroenterol. Hepatol. 2002,17,1078-83.
79. Greten, FR; Karin, M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004,206,193-9.
80. Paradisi, A; Maisse, C; Bernet, A; Coissieux, MM; Maccarrone, M; Scoazec, JY; Mehlen, P.NF-kappaB regulates netrin-1 expression and affects the conditional tumor suppressive activity of the netrin-1 receptors. Gastroenterology2008,135,1248-57.
81. Popivanova, BK; Kitamura, K; Wu, Y; Kondo, T; Kagaya, T; Kaneko, S; Oshima, M; Fujii, C; Mukaida, N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 2008,118,560-70.
82. Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 2009,9,361-71.
83. Becker, C; Fantini, MC; Schramm, C; Lehr, HA; Wirtz, S; Nikolaev, A; Burg, J; Strand, S; Kiesslich, R; Huber, S; Ito, H; Nishimoto, N; Yoshizaki, K; Kishimoto, T; Galle, PR; Blessing, M; Rose-John, S; Neurath, MF. TGF-βsuppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling," Immunity 2004, 21, 491-501.
84. Strand, S; Kiesslich, R; Huber, S; Ito, H; Nishimoto, N; Yoshizaki, K; Kishimoto, T; Galle, PR; Blessing, M; Rose-John, S; Neurath, MF. TGF-ßsuppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling," Immunity 2004, 21, 491-501.
85. Stolfi, C; Rizzo, A; Franzè, E; Rotondi, A; Fantini, MC; Sarra, M; Caruso, R; Monteleone, I; Sileri, P; Franceschilli, L; Caprioli, F; Ferrero, S; MacDonald, TT; Pallone, F; Monteleone G. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J. Exp. Med. 2011,208,2279-2290.
86. Hanada, T; Kobayashi, T; Chinen, T; Saeki, K; Takaki, H; Koga, K; Minoda, Y; Sanada, T; Yoshioka, T; Mimata, H; Kato, S; Yoshimura, A. IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J. Exp. Med. 2006,203,1391-7.
87. Vetrano, S; Borroni, EM; Sarukhan, A; Savino, B; Bonecchi, R; Correale, C; Arena, V; Fantini, M; Roncalli, M; Malesci, A; Mantovani, A; Locati, M; Danese, S. The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6. Gut 2010,59,197-206.
88. Fukata, M; Chen, A; Vamadevan, AS; Cohen, J; Breglio, K; Krishnareddy, S; Hsu, D; Xu, R; Harpaz, N; Dannenberg, AJ; Subbaramaiah, K; Cooper, HS; Itzkowitz, SH; Abreu, MT. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007,133,1869-1881.
89. Fukata, M; Chen, A; Klepper, A; Krishnareddy, S; Vamadevan, AS; Thomas, LS; Xu, R; Inoue, H; Arditi, M; Dannenberg, AJ; Abreu, MT. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 2006,131,862-877.
90. Hernandez, Y; Sotolongo, J; Breglio, K; Conduah, D; Chen, A; Xu, R; Hsu, D; Ungaro, R; Hayes, LA; Pastorini, C; Abreu, MT; Fukata, M. The role of prostaglandin E2(PGE 2) in Toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia. BMC Gastroenterology 2010,10,82.
91. Salcedo, R; Worschech, A; Cardone, M; Jones, Y; Gyulai, Z; Dai, RM; Wang, E; Ma, W; Haines, D; O'hUigin, C; Marincola, FM; Trinchieri G. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J. Exp. Med. Vol 2010,207,1625-1636.
92. Garlanda, C; Riva, F; Veliz, T; Polentarutti, N; Pasqualini, F; Radaelli, E; Sironi, M; Nebuloni, M; Zorini, EO; Scanziani, E; Mantovani, A. Increased susceptibility to colitisassociated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res. 2007,67,6017-6021.
93. Liao, J; Seril, DN; Lu, GG; Zhang, M; Toyokuni, S; Yang, AL; Yang, GY. Increased susceptibility of chronic ulcerative colitis-induced carcinoma development in DNA repair enzyme Ogg1 deficient mice. Mol. Carcinog. 2008,47,638-646.
94. Tanaka, T; de Azevedo, MB; Durán, N; Alderete, JB; Epifano, F; Genovese, S; Tanaka, M; Tanaka, T; Curini, M. Colorectal cancer chemoprevention by 2 beta-cyclodextrin inclusion compounds of auraptene and 4'-geranyloxyferulic acid. Int. J. Cancer 2010,126,830-40.
95. Cui, X; Jin, Y; Poudyal, D; Chumanevich, AA; Davis, T; Windust, A; Hofseth, A; Wu, W; Habiger, J; Pena, E; Wood, P; Nagarkatti, M; Nagarkatti, PS; Hofseth, L. Mechanistic insight into the ability of American ginseng to suppress colon cancer associated with colitis. Carcinogenesis 2010,31,1734-41.
96. Dougherty, U; Mustafi, R; Wang, Y; Musch, MW; Wang, CZ; Konda, VJ; Kulkarni, A; Hart, J; Dawson, G; Kim, KE; Yuan, CS; Chang, EB; Bissonnette, M. American ginseng suppresses Western diet-promoted tumorigenesis in model of inflammation-associated colon cancer: role of EGFR. BMC Complement Altern Med. 2011,11,11.
97. Zhao, Y; Lee, MJ; Cheung, C; Ju, JH; Chen, YK; Liu, B; Hu, LQ; Yang, CS. Analysis of Multiple Metabolites of Tocopherols andTocotrienols in Mice and Humans. J. Agric. Food Chem. 2010,58,4844-4852.
98. Cui, X; Jin, Y; Hofseth, AB; Pena, E; Habiger, J; Chumanevich, A; Poudyal, D; Nagarkatti, M; Nagarkatti, PS; Singh, UP; Hofseth, LJ. Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev. Res. (Phila) 2010,3,549-559.
99. Li, H; Wu, WK; Li, ZJ; Chan, KM; Wong, CC; Ye, CG; Yu, L; Sung, JJ; Cho, CH; Wang, M. 2,3',4,4',5'-Pentamethoxy-trans-stilbene, a resveratrol derivative, inhibits colitis-associated colorectal carcinogenesis in mice. Br. J. Pharmacol. 2010,160,1352-61.
100. Murakami, A; Takahashi, D; Kinoshita, T; Koshimizu, K; Kim, HW; Yoshihiro, A; Nakamura, Y; Jiwajinda, S; Terao, J; Ohigashi, H. Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the alpha, beta-unsaturated carbonyl group is a prerequisite. Carcinogenesis. 2002,23,795-802.
101. Ravichandran, K; Velmurugan, B; Gu, M; Singh, RP; Agarwal, R. Inhibitory effect of silibinin against azoxymethane-induced colon tumorigenesis in A/J Mice. Clin. Cancer Res. 2010,16,4595-606.
102. Cheung, KL; Khor, TO; Huang, MT; Kong, AN. Differential in vivo mechanism of chemoprevention of tumor formation in azoxymethane/dextran sodium sulfate mice by PEITC and DBM. Carcinogenesis 2010,31,880-5.
103. Oyama, T; Yasui, Y; Sugie, S; Koketsu, M; Watanabe, K; Tanaka, T. Dietary tricin suppresses inflammation-related colon carcinogenesis in male Crj: CD-1 mice. Cancer Prev. Res. (Phila) 2009,2,1031-8.
104. Feng, Y; Finley, JW; Davis, CD; Becker, WK; Fretland, AJ; Hein, DW. Dietary selenium reduces the formation of aberrant crypts in rats administered 3,2'-dimethyl-4-aminobiphenyl. Toxicol. Appl. Pharmacol. 1999,157,36-42.
105. Finley, JW; Davis, CD. Selenium (Se) from high-selenium broccoli is utilized differently than selenite, selenate and selenomethionine, but is more effective in inhibiting colon carcinogenesis. Biofactors 2001, 14,191-196.
106. Kim, JH; Hue, JJ; Kang, BS; Park, H; Nam, SY; Yun, YW; Kim, JS; Lee, BJ. Effects of selenium on colon carcinogenesis induced by azoxymethane and dextran sodium sulfate in mouse model with high-iron diet. Lab. Anim. Res. 2011,27,9-18.
107. Krehl, S; Loewinger, M; Florian, S; Kipp, AP; Banning, A; Wessjohann, LA; Brauer, MN; Iori, R; Esworthy, RS; Chu, FF; Brigelius-Flohé, R. Glutathione peroxidase-2 and selenium decreased inflammation and tumors in a mouse model of inflammation-associated carcinogenesis whereas sulforaphane effects differed with selenium supply. Carcinogenesis 2012,33,620-8.
108. Ock, CY; Kim, EH; Choi, DJ; Lee, HJ; Hahm, KB; Chung, MH. 8-Hydroxy-deoxyguanosine: not mere biomarker for oxidative stress, but remedy for oxidative stress-implicated gastrointestinal diseases. World J. Gastroenterol. 2012,18,302-8.
109. Ock, CY; Kim, EH; Hong, H; Hong, KS; Han, YM; Choi, KS; Hahm, KB; Chung MH. Prevention of colitis-associated colorectal cancer with 8-hydroxydeoxyguanosine. Cancer Prev. Res.(Phila) 2011,4,1507-1521.
110. Yamaguchi, K; Shiozaki, K; Moriya, S; Koseki, K; Wada, T; Tateno, H; Sato, I; Asano, M; Iwakura, Y; Miyagi, T. Reduced susceptibility to colitis-associated colon carcinogenesis in mice lacking plasma membrane-associated sialidase. PLoS One 2012,7,e41132.
111. Jauch, D; Martin, M; Schiechl, G; Kesselring, R; Schlitt, HJ; Geissler, EK; Fichtner-Feigl, S. Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut 2011,60,1678-86.
112. D'Errico, I; Salvatore, L; Murzilli, S; Lo Sasso, G; Latorre, D; Martelli, N; Egorova, AV; Polishuck, R; Madeyski-Bengtson, K; Lelliott, C; Vidal-Puig, AJ; Seibel, P; Villani, G; Moschetta, A. Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1alpha) is a metabolic regulator of intestinal epithelial cell fate. Proc. Natl. Acad. Sci. USA 2011,108,6603-8.
113. Tanaka, T; Kohno, H; Yoshitani, S; Takashima, S; Okumura, A; Murakami, A; Hosokawa, M. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. 2001,61,2424-8.
114. Wang, D; DuBois, RN. Peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer. Gastroenterol. Clin. North Am 2010,39,697-707.
115. Takahashi, N; Okumura, T; Motomura, W; Fujimoto, Y; Kawabata, I; Kohgo, Y. Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett. 1999,455,135-9.
116. Kohno, H; Yoshitani, S; Takashima, S; Okumura, A; Hosokawa, M; Yamaguchi, N; Tanaka, T. Troglitazone, a ligands for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats. Jpn J. Cancer Res. 2001,92,396-403.
117. Su, W; Necela, BM; Fujiwara, K; Kurakata, S; Murray, NR; Fields, AP; Thompson, EA. The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethanetreated miceInt. J. Cancer 2008, 123, 991-7.
118. Osawa, E; Nakajima, A; Wada, K; Ishimine, S; Fujisawa, N; Kawamori, T; Matsuhashi, N; Kadowaki T; Ochiai, M; Sekihara, H; Nakagama, H. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003,124,361-7.
119. Chumanevich, AA; Poudyal, D; Cui, X; Davis, T; Wood, PA; Smith, CD; Hofseth, LJ. Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis 2010,31,1787-93.
120. Suzuki, S; Sakamoto, S; Mitamura, T; Sassa, S; Kudo, H; Yamashita, Y. Preventive effects of sulphasalazine on colorectal carcinogenesis in mice with ulcerative colitis. In Vivo 2000,14,463-6.
121. Clapper, ML; Gary, MA; Coudry, RA; Litwin, S; Chang, WC; Devarajan, K; Lubet, RA; Cooper, HS. 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm Bowel Dis. 2008,14,1341-7.
122. Kohno, H; Suzuki, R; Yasui, Y; Miyamoto, S; Wakabayashi, K; Tanaka, T. Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice. Clin. Cancer Res. 2007,13,2519-25.
123. Stolfi, C; Sarra, M; Caruso, R; Fantini, MC; Fina, D; Pellegrini, R; Palmieri, G; Macdonald, TT; Pallone, F; Monteleone, G. Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamine. Gastroenterology 2010,138,221-30.
124. Kohno, H; Suzuki, R; Sugie, S; Tanaka, T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 2005,5,46.
125. Glauben, R; Batra, A; Stroh, T; Erben, U; Fedke, I; Lehr, HA; Leoni, F; Mascagni, P; Dinarello, CA; Zeitz, M; Siegmund, B. Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut 2008,57,613-22.